Veracyte VCYT
Veracyte, Inc. · Nasdaq · Services-Medical Laboratories
$24.00-54.30%close on Nov. 5, 2026 · volume 15.0M · Yahoo Finance
Price, last 53 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 27, 2026 | Jens Holstein director | Sold 10b5-1 plan | 7,500 | $50.00 | $375,000 |
| Oct. 27, 2026 | Karin Eastham director | Sold 10b5-1 plan | 14,850 | $50.00 | $742,573 |
| Oct. 19, 2026 | Muna Bhanji director | Sold 10b5-1 plan | 1,864 | $43.70 | $81,457 |
| Sept. 24, 2026 | Jens Holstein director | Sold 10b5-1 plan | 7,500 | $47.00 | $352,500 |
| Sept. 21, 2026 | John Leite Global Chief Commercial Off | Sold 10b5-1 plan | 4,015 | $40.00 | $160,600 |
| Sept. 14, 2026 | Jens Holstein director | Sold 10b5-1 plan | 5,000 | $40.95 | $204,747 |
| Sept. 4, 2026 | Phillip G. Febbo Chief Scientific & Med Officer | Sold 10b5-1 plan | 13,110 | $43.05 $42.89-$43.66 | $564,410 |
| Sept. 4, 2026 | Rebecca Chambers Chief Financial Officer | Sold 10b5-1 plan | 3,652 | $43.10 $42.81-$43.71 | $157,394 |
| Sept. 4, 2026 | Annie McGuire EVP, General Counsel | Sold 10b5-1 plan | 3,254 | $43.09 $42.79-$43.67 | $140,212 |
| Sept. 1, 2026 | Muna Bhanji director | Sold 10b5-1 plan | 1,864 | $42.97 | $80,096 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 19 →Results of operations and financial condition · Other events · Financial statements and exhibits
AI summary, unreviewedVeracyte Q3 2026 Revenue $151.8 Million (+15%) and Non-GAAP EPS $0.51 Beat Consensus; Narrows 2026 Revenue Guidance to $590-$593 Million and Announces $100 Million Buyback